TRACON Pharma Terminates Phase 3 TAPPAS Trial - Quick Facts

(RTTNews) - TRACON Pharmaceuticals, Inc. (TCON) announced Friday that its Phase 3 TAPPAS trial was terminated for futility based on the recommendation of the Independent Data Monitoring Committee (IDMC).

The trial was evaluating TRC105 in combination with Votrient (pazopanib) in patients with advanced or metastatic angiosarcoma.

The termination followed a review by the IDMC of interim unblinded safety and efficacy data from more than 120 patients enrolled in the trial at the time of the analysis.

TRACON said it will work with investigators to appropriately conclude the study in a manner consistent with the best interests of each patient. Data from this study will be analyzed and submitted for presentation at an upcoming scientific congress.

TRACON is a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and also wet age-related macular degeneration through its license to Santen Pharmaceutical Co. Ltd.